FDA Inspection
Boehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim Pharma Gmbh & Co Kg – FDA Inspection, Apr 5, 2019
Record Details
This FDA Inspection record concerns Boehringer Ingelheim Pharma Gmbh & Co Kg, with an inspection on April 5, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · dbf348fc-bd1b-46d8-8ac0-0e7e2889aa61
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1086418
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
2- 21 CFR 211.160(a)Lab controls established, including changes
- 21 CFR 211.192Investigations of discrepancies, failures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Boehringer Ingelheim Pharma Gmbh & Co Kg
13| Date | Classification | Office | Project area |
|---|---|---|---|
| July 22, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 19, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 15, 2019 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| October 19, 2018 | Not classified | Office of Inspections and Investigations | |
| September 21, 2018 | Not classified | Office of Inspections and Investigations |
Other documents for Boehringer Ingelheim Pharma Gmbh & Co Kg
- FDA Inspection 1208927 - 2022-07-22
- FDA Inspection 1102691 - 2019-09-19
- FDA Inspection 1107587 - 2019-08-15
- FDA Inspection 1072835 - 2018-10-19
- FDA Inspection 1069908 - 2018-09-21
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.